These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of basiliximab in pediatric renal transplantation. García-Meseguer C; Roldán M; Melgosa M; Alonso A; Peña A; Espìnosa L; Navarro M Transplant Proc; 2002 Feb; 34(1):102-3. PubMed ID: 11959206 [No Abstract] [Full Text] [Related]
4. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience. Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494 [No Abstract] [Full Text] [Related]
5. Conversion from cyclosporine to tacrolimus is preferred by pediatric renal transplant recipients: a focus on opinions and outcomes. Sundberg AK; Smith LD; Somerville KT; Cox R; Sherbotie JR Transplant Proc; 2002 Aug; 34(5):1951-2. PubMed ID: 12176640 [No Abstract] [Full Text] [Related]
6. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection. Burke GW; Ciancio C; Blomberg BB; Rosen A; Suzart K; Roth D; Kupin W; Esquenazi V; Miller J Transplant Proc; 2002 Aug; 34(5):1610-1. PubMed ID: 12176505 [No Abstract] [Full Text] [Related]
7. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Grewal HP; Siegel CT; Pellar S; Josephson MA; Thistlethwaite JR Transplant Proc; 1998 Jun; 30(4):1538-40. PubMed ID: 9636625 [No Abstract] [Full Text] [Related]
8. Effects of three immunosuppressive regimens on CD4 helper function, B cell monocyte and cytokine responses in renal transplant recipients: 4-month follow-up of a prospective randomized study. Weimer R; Streller S; Staak A; Heilke M; Li D; Dietrich H; Daniel V; Feustel A; Rainer L; Zinn S; Friemann S; Ernst W; Grimm H; Padberg W; Zimmermann T; Opelz G Transplant Proc; 2002 Sep; 34(6):2377-8. PubMed ID: 12270445 [No Abstract] [Full Text] [Related]
9. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group. Forsythe J Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049 [No Abstract] [Full Text] [Related]
10. Conversion from cyclosporine-based immunosuppression to tacrolimus/mycophenolate mofetil in patients with refractory and ongoing acute renal allograft rejection. Boratyńska M; Banasik M; Patrzałek D; Klinger M Ann Transplant; 2006; 11(2):51-6. PubMed ID: 17494290 [TBL] [Abstract][Full Text] [Related]
11. Conversion of renal transplant immunosuppression from tacrolimus (FK 506) to cyclosporine: a single center experience. Ichikura H; Tanabe K; Tokumoto T; Shimuzu T; Ishikawa N; Harano M; Inui M; Manu M; Ito S; Shimmura H; Okuda H; Yagisawa T; Fuchinoue S; Toma H Transplant Proc; 2000 Nov; 32(7):1733-5. PubMed ID: 11119911 [No Abstract] [Full Text] [Related]
12. Randomized trial of tacrolimus in combination with mycophenolate mofetil versus cyclosporine with mycophenolate mofetil in cadaveric renal transplant recipients with delayed graft function. Liu B; Lin ZB; Ming CS; Zhang WJ; Chen ZS; Sha B; Zeng FJ; Chen S Transplant Proc; 2003 Feb; 35(1):87-8. PubMed ID: 12591319 [No Abstract] [Full Text] [Related]